Physician profile
Miranda Coplien
NPI 1336804640
$1,187.67
in general payments reported to CMS, 2019-2025
16 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $125 · 2022: $330 · 2023: $561 · 2024: $172.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $733.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $733.04 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $333.65 | 2021-2024 | |
| E.R. Squibb & Sons, L.L.C. | $188.88 | 2022-2023 | Zeposia |
| Janssen Biotech, INC. | $112.21 | 2023-2024 | Stelara |
| Genzyme Corporation | $111.17 | 2022-2023 | |
| Gilead Sciences, INC. | $91.63 | 2021 | |
| Celgene Corporation | $66.62 | 2022-2024 | Zeposia |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $66.34 | 2021-2024 | Plenvu, Xifaxan |
| Qol Medical, LLC | $58.80 | 2023-2024 | Sucraid, Sucraid |
| Lilly USA, LLC | $27.60 | 2024 | Omvoh |
| Mauna Kea Technologies, INC. | $26.95 | 2022 | |
| Ardelyx, INC. | $23.10 | 2023 | Ibsrela |
| Phathom Pharmaceuticals, INC. | $18.93 | 2023 | Voquezna |
| Merck Sharp & Dohme LLC | $18.39 | 2023 | Dificid |
| Medtronic, INC. | $15.79 | 2022 | |
| Regeneron Healthcare Solutions, INC. | $14.44 | 2024 | Dupixent |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $13.17 | 2023 | Entyvio |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Miranda Coplien listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.